Form 4: Ionis Pharmaceuticals Director Michael Yang Receives Significant Equity Grants

Ionis Pharmaceuticals Director Michael J. Yang was granted 11,518 non-qualified stock options and 5,220 restricted stock units on July 1, 2025, as part of the company's non-employee director compensation policy.

Summary

• Director Michael J. Yang received a grant of 11,518 non-qualified stock options on July 1, 2025, with an exercise price of $39.94.
• These stock options vest 100% on the first anniversary of the grant date or the next regularly scheduled annual meeting of stockholders, whichever occurs earlier, and are set to expire on June 30, 2035.
• Yang also received a grant of 5,220 Restricted Stock Units (RSUs) on July 1, 2025.
• Each RSU represents a contingent right to receive one share of Ionis common stock or its equivalent cash value.
• The RSUs vest 100% on the first anniversary of the grant date or the next regularly scheduled annual meeting of stockholders, whichever occurs earlier, with delivery to occur on July 15th following the vesting date.
• These grants were adjusted downward to ensure Michael Yang's total annual equity compensation for 2025 does not exceed $450,000, based on the aggregate grant date fair value as determined by FASB Topic ASC 718.
• Following these transactions, Michael Yang beneficially owns 11,518 non-qualified stock options and 13,159 Restricted Stock Units.

Sentiment

Score: 7

Explanation: The document reflects a standard, positive corporate governance practice of aligning director incentives with shareholder value through equity compensation, within a defined policy limit. It is a routine disclosure without negative implications for the company's operations or financial health.

Positives

• The equity grants align the director's financial interests directly with shareholder value creation.
• The company's Non-Employee Director Compensation Policy includes a cap of $450,000 on annual equity compensation, demonstrating a structured and fiscally responsible approach to director remuneration.

Negatives

• The stock options and RSUs are subject to vesting periods, meaning the director does not immediately gain full ownership or liquidity.
• The ultimate value realized from these equity grants is dependent on the future performance of Ionis Pharmaceuticals' stock price.

Future Outlook

The document primarily details past and future vesting schedules for equity grants, but does not provide broader forward-looking statements or guidance on company performance.

Industry Context

This disclosure of director equity compensation is a standard practice across publicly traded companies, particularly in the biotechnology and pharmaceutical sectors, serving to align the interests of board members with those of shareholders and to attract and retain qualified talent.

Comparison to Industry Standards

• The practice of granting equity (stock options and RSUs) to non-employee directors is a common industry standard for aligning interests and attracting talent.
• The specific cap of $450,000 for annual equity compensation is within the typical range for directors at companies of similar market capitalization and industry, though specific benchmarks would require a deeper compensation study.
• Vesting schedules tied to anniversaries or annual meetings are standard for director equity grants.

Corporate Governance

Stakeholder Impact

• Shareholders: The equity compensation aligns the director's financial interests with shareholder value creation, potentially leading to better long-term decision-making. The cap on compensation also provides transparency and control over director remuneration.

Next Steps

• The granted stock options and RSUs will vest on the first anniversary of the grant date (July 1, 2026) or the next regularly scheduled annual meeting of stockholders, whichever occurs earlier.
• RSUs will be delivered to the reporting person on July 15th following their vesting date.

Key Dates

Recommendation

Keywords

Ionis Pharmaceuticals, IONS, SEC Form 4, Director Compensation, Stock Options, Restricted Stock Units, Equity Grant, Beneficial Ownership, Corporate Governance, Executive Compensation